Emergent BioSolutions has begun the dosing of volunteer subjects in a clinical study in Ho Chi Minh City, Vietnam, to evaluate the safety and immunogenicity of the company's next-generation single-dose oral typhoid vaccine.
This trial is the first study in a Phase II clinical program involving adult Vietnamese volunteers in a series of age-descending trials prior to a Phase III efficacy study in children. A surveillance study will also be conducted in parallel to the Phase II program to determine demographics and prevalence of the disease in the region.
The investigational oral typhoid vaccine, if successful, would provide travelers the option of an effective, easy-to-use single-dose regimen that can be taken before visiting high-risk areas. Current vaccines require either an injection or a three-to-four oral dose regimen.